Solara Active Pharma Sciences Limited has informed the Exchange regarding a Press Release dated October 16, 2026, titled "Solara''s Q2 FY 27 revenue grows 33% to INR 4,178 Mn and EBITDA more than doubles to INR 769 Mn, its best quarter in five years"

Corporate Office: Solara Active Pharma Sciences Limited TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in Website: www.solara.co.in Date: October 16, 2026 The BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 541540, 890202 Scrip Code: SOLARA, SOLARAPP1 Dear Sir / Madam, Subject: Press Release Pursuant to the Regulation 30 of the SEBI Listing Regulations, we are enclosing herewith a copy of the Press Release on financial results for the quarter and half year ended September 30, 2026. The same will also be made available on the website of the Company https://solara.co.in/investor-relations/investor-update/ The Press Release (along with Earnings Presentation) for the Board Meeting held on Friday, October 16, 2026, issued by the Company titled: Solara’s Q2 FY27 revenue grows 33% to INR 4,178 Mn and EBITDA more than doubles to INR 769 Mn, its best quarter in five years This is for your kind information and records. Thanking You, Yours Faithfully, For Solara Active Pharma Sciences Limited Pooja Jaya Kumar Company Secretary & Compliance Officer ICSI Membership No.: A57415 Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636 Registered Office: ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703; Tel: +91-22-20870033 Solara’s Q2 FY27 revenue grows 33% to INR 4,178 Mn and EBITDA more than doubles to INR 769 Mn, its best quarter in five years BASE BUSINESS (EX-IBUPROFEN) IBUPROFEN BUSINESS OVERALL BUSINESS REVENUE REVENUE REVENUE INR 3,273 Mn, up 37% YoY and 6% QoQ INR 905 Mn, up 21% YoY and 18% QoQ INR 4,178 Mn, up 33% YoY and 9% QoQ EBITDA EBITDA EBITDA INR 771 Mn, up 68% YoY and 7% QoQ Loss of INR 2 Mn, narrowed from INR 87 Mn INR 769 Mn, up 118% YoY and 21% QoQ in Q1’27 ≫ EBITDA margin expanded ~440 bps YoY to ≫ Business is now close to breakeven INR 285 Mn, against a loss of INR 101 Mn in 23.6%, despite continued input cost Q2’26 pressures ≫ Highest quarterly EBITDA and PAT in the last five years Solara Active Pharma Sciences Limited Q2’27 Earnings Update | Oct 16, 2026 Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", “seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute “forward-looking statements” These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Page 2 Q2’27 at a glance: revenue up 37% in Base and 21% in Ibuprofen, taking overall revenue up 33% to INR 4,178 Mn and EBITDA up 118% BASE BUSINESS REVENUE BASE BUSINESS GROSS MARGIN BASE BUSINESS EBITDA INR 3,273 Mn INR 1,645 Mn INR 771 Mn (50.3%) (23.6%) ▲+37% YoY | +6% QoQ ▲+29% YoY | +4% QoQ ▲+68% YoY | +7% QoQ | +440 bps YoY IBUPROFEN REVENUE IBUPROFEN GROSS MARGIN IBUPROFEN EBITDA INR 905 Mn INR 327 Mn INR (2) Mn (36.1%) (-0.2%) ▲+21% YoY | +18% QoQ ▲+20% YoY | +47% QoQ Loss narrowed from INR 87 Mn in Q1’27 OVERALL REVENUE OVERALL GROSS MARGIN OVERALL EBITDA INR 4,178 Mn INR 1,972 Mn INR 769 Mn (47.2%) (18.4%) ▲+33% YoY | +9% QoQ ▲+28% YoY | +9% QoQ ▲+118% YoY | +21% QoQ | +720 bps YoY PAT EARNINGS PER SHARE NET DEBT (SEP’26) INR 285 Mn INR 5.92 INR 5,000 Mn per share ▲+75% QoQ | vs loss of INR 101 Mn in Q2’26 ▲+68% QoQ | vs INR (2.36) in Q2’26 ▼Down 19% (INR 1,141 Mn) vs Mar’26 Page 3 Base business led the overall growth, revenue up 33% YoY and 9% QoQ, EBITDA more than doubles and PAT remains positive at INR 285 Mn “This is our best quarter in five years, and the improvement is coming from every part of the business.” Our Base business continues to lead our growth. Revenue grew 37% to INR 3,273 Mn, staying above INR 3,000 Mn for the third quarter in a row, and EBITDA grew 68% to INR 771 Mn, with the margin up about 440 bps to 23.6% even as raw material costs rose. Sandeep Rao Ibuprofen is turning around. Revenue grew 21% over last year and 18% over last quarter, and the Managing Director & CEO business is now close to breakeven, from a loss margin of 21% just two quarters ago. As a result, overall revenue grew 33% to INR 4,178 Mn and EBITDA more than doubled, up 118% to INR 769 Mn. We are firmly back in profit, with PAT of INR 285 Mn against a loss of INR 101 Mn a year ago. Net debt to EBITDA is down to about 1.8x from 3.2x at the end of FY26, giving us room to keep investing in growth. Sandeep Rao, Managing Director & CEO Page 4 Base business revenue up 37% YoY to INR 3,273 Mn, a third straight quarter above INR 3,000 Mn, with EBITDA up 68% to INR 771 Mn Q2’27 Base Business performance (₹ Million) Key Updates The Base business continued its growth momentum, Particulars Q2’27 Q1’27 QoQ% Q2’26 YoY% H1’27 H1’26 YoY% delivering Revenue, Gross margin and EBITDA growth of 01 37%, 29% and 68% YoY respectively in Q2’27; sequentially, Revenue, Gross margin and EBITDA grew by Revenue 3,273 3,077 6% 2,391 37% 6,350 4,878 30% 6%, 4% and 7% respectively. Gross margins* 1,645 1,580 4% 1,273 29% 3,225 2,719 19% EBITDA growth outpaced revenue growth both YoY and QoQ, expanding EBITDA margin to 23.6% (vs 19.2% in Gross margins % 50.3% 51.3% 53.2% 50.8% 55.7% Q2’26, +440 bps) reflecting improved business and operational efficiency. EBITDA 771 722 7% 459 68% 1,493 1,130 32% Gross margin stood at 50.3% (vs 53.2% in Q2’26), amid EBITDA Margins % 23.6% 23.5% 19.2% 23.5% 23.2% 03 continued inflationary pressure on select raw materials and solvents linked to the West Asia crisis. BASE REVENUE BASE EBITDA EBITDA MARGIN INR 3,273 Mn INR 771 Mn 23.6% Regulated markets continue to contribute ~78% of revenues on account of healthy product mix. ▲37% YoY | 6% QoQ ▲68% YoY | 7% QoQ ▲+440 bps YoY *Gross margins are calculated after S&D cost. Base business excludes commodity Ibuprofen business Page 5 Base business growth is consistent: revenue up 37% and EBITDA up 68% in a year, while net debt to EBITDA falls to 1.8x Revenue (INR Mn) | ▲37% YoY Gross margins (INR Mn & %) | ▲29% YoY EBITDA (INR Mn & %) | ▲68% YoY 15,237%3 15,356%5 15,644%8 15,518%0 15,604%5 459 520 2769%6 2742%2 2747%1 3,273 3,070 3,077 2,391 2,466 Q2'26 Q3'26 Q4'26 Q1'27 Q2'27 Q2'26 Q3'26 Q4'26 Q1'27 Q2'27 Q2'26 Q3'26 Q4'26 Q1'27 Q2'27 Net Debt * (INR Mn) | ▼20% YoY Net Debt to EBITDA# (x) | 3.2x to 1.8x Base business delivered YoY growth of 37% in Revenue and 68% in EBITDA, with sequential growth in Revenue, Gross margin and EBITDA. LTD STD 6,233 6,300 6,141 4,795 5,000 1.9 Healthy profitability: ~50% gross margin and 23.6% EBITDA margin in Q2’27. 4,761 4,995 4,504 2,710 3,301 Net debt reduced by INR 1,141 Mn in H1’27 to INR 5,000 2,290 1,472 1,305 1,637 1,494 Mn; Net debt to EBITDA improved to ~1.8x (from 3.2x in FY26), strengthening the balance sheet. Q2'26 Q3'26 Q4'26 Q1'27 Q2'27 FY26 Q1'27 Q2'27 * represents the consolidated Net debt for the company # Net debt to consolidated EBITDA; FY26 on full-year EBITDA (INR 1,917 Mn), Q1’27 on annualisedQ1’27 E [Showing first 8,000 characters — download PDF for full document]